Can Churches be Protectors of Public Health?
Over the past two years of living with COVID-19, many churches have had to think in new ways.
The Curious Case of Dr. Xiulu Ruan
Dr. Ruan holds the world record for the most board certifications of any physician. But today he finds himself before...
When Behavior Becomes a Disease
Obesity is notoriously difficult to treat. We introduce food logs and recommend diet and exercise, with varying results. Instead, we...
The Chronic Disease of Debt
Medical debt in the United States has reached pandemic proportions. It is now the largest source of debt in the...
How Long Does Protective Immunity Against COVID-19 Last After Infection or Vaccination?
Researchers are beginning to better understand how existing immunity protects against reinfection and the prevention of severe COVID-19 that can...
Ninety Percent of Drugs Fail Clinical Trials
It takes 10 to 15 years and around $1 billion to develop a successful drug. Despite these investments in time...
Some Cancers are Preventable with a Vaccine
These viruses don’t cause cancer until long after they infect a person. Rather, the viruses teach the cells how to...
Not Everyone is Male or Female
Although the medical establishment is now recognizing that sex is not binary, society as a whole has been slow to...
In Research Studies and in Real Life, Placebos have a Powerful Healing Effect on the Body and Mind
Could the placebo effect tell us something new about the power of our minds and how our bodies are able...
One in Four Americans are Covered by Medicaid or CHIP
As of July 2021, a total of 83.6 million Americans were insured through either Medicaid or the Children’s Health Insurance...
The War on Drugs is a War on Right Thinking
The way we think creates the conclusions we make. Unfortunately, faulty logic has led to failed drug policy. It is...
When COVID-19 Policy becomes Biology
COVID-19 challenged our fundamental assumptions on science and values, showing us how often we are wrong without realizing it. The...
Videos
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more